Evidence suggests that incretin-based dual agonist pharmacotherapy is helpful in persons with obesity. Mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, may have efficacy in ...
Hosted on MSN
Novo Nordisk shares pop 5% after Wegovy pill trial shows 'significant' weight reduction
Trial results showed the "Wegovy pill" led to average weight reduction of 16.6% after 64 weeks, Novo Nordisk said. The company's Chief Science Officer Martin Holst Lange told CNBC that oral treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback